Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Inv...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 1, 2023

BEST-EVER FIRST QUARTER AND MARCH SALES FOR KIA AMERICA • Wild Rivers Waterpark Drops Dates For Camp Wild Rivers Junior Lifeguards, a One-of-a-Kind Weekly Summer Camp for Orange County, • Bass Named Women In Trucking Association's 2023 Driver of the Year • RYVYL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against RYVYL • BLOCK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Block • Statement by Minister Hussen for Sikh Heritage Month • UNITE HERE Local 11 Rallies with LA Councilmember Curren Price to Endorse Boycott of Tommie and Thompson Hotels • REDWIRE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and D • REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries • INVIVYD DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inv • UNice Hair Launches "UNice Empowering Workshop" Event • HONDA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Honda • New Birth Missionary Baptist Church Announces Outreach Activities, Plans for Easter Weekend • Why We Need to Ban ChatGPT in Elementary Schools • Statement by the Ministers of Crown-Indigenous Relations, Indigenous Services, and Northern Affairs on the Catholic Church's re • TGT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Target Corp. Investors with Substantial Losses Have Opp • TUP NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Tupperware Brands Corporation Investors to Secure Counsel Before Importa • Realty Income Publishes Third Annual Sustainability Report • 160 Driving Academy Celebrates Women's History Month • REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

BOSTON , February 02 /Businesswire/ - Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting Thursday, February 16, 2023 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March 2, 2023. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.